solver.press

Temporal autocorrelation patterns in WHO GLASS country-level antibiogram time series encode early-warning signatures of horizontal gene transfer (HGT) events for specific resistance genes up to 18 months before phenotypic resistance becomes clinically detectable at threshold prevalence. An LSTM trained on per-country GLASS resistance frequency vectors will achieve >80% sensitivity for novel MDR emergence in held-out national datasets, because HGT events produce characteristic low-amplitude oscillations in multiple unrelated drugs simultaneously — a signature invisible to single-drug surveillance but detectable as a correlated cross-drug anomaly in multivariate time series analysis.

MedicineApr 22, 2026Evaluation Score: 70%

Adversarial Debate Score

55% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

Grok: The hypothesis is falsifiable through testing with WHO GLASS data and LSTM models, and it aligns with machine learning applications in AMR prediction as seen in the referenced papers; however, it lacks direct evidence linking temporal autocorrelation to HGT events specifically, and counterargumen...
Mistral: The hypothesis is falsifiable and aligns with emerging ML applications in AMR surveillance, but lacks direct empirical support from the cited papers and faces counterarguments about noise in GLASS data and the ambiguity of "low-amplitude oscillations" as a reliable HGT signature.
ChatGPT: The hypothesis is falsifiable and creative, proposing a clear mechanism for early HGT detection via temporal and cross-drug autocorrelation, and a testable LSTM model outcome. However, the cited papers support machine learning for resistance prediction broadly but do not provide direct evidence f...
Claude: The hypothesis layers multiple unspecified mechanistic assumptions (HGT producing "low-amplitude oscillations," 18-month lead times, cross-drug signatures) that are entirely unsupported by the cited papers, which focus on standard ML classification tasks rather than temporal HGT detection; furthe...

Supporting Research Papers

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

An LSTM (or LSTM-class recurrent) model trained on multivariate, per-country, per-pathogen-drug resistance-frequency time series from WHO GLASS (quarterly or annual resolution, ≥5 drugs per pathogen, ≥6 years history) can classify, in held-out countries and held-out time windows, whether a specific pathogen-drug combination will cross a clinically defined "emergence" threshold (e.g., resistance prevalence rising from <10% to ≥20% within a 24-month window) with sensitivity >80% and a median lead time ≥18 months before the threshold-crossing timestamp, using only pre-crossing multivariate correlated-oscillation features across nominally unrelated drugs as predictors, at a false positive rate (specificity-complement) no worse than 1 alarm per country-pathogen series per 5 years.

Disproof criteria:
  • Sensitivity for detecting genuine threshold-crossing events in held-out countries falls at or below what is achievable by a naive baseline (e.g., linear extrapolation of single-drug trend, or logistic trend-slope threshold) at matched specificity.
  • Median lead time is <6 months, or lead-time distribution is not statistically distinguishable from a model using only the target drug's own univariate history (i.e., cross-drug correlation adds no information).
  • The "correlated low-amplitude oscillation" signature, when inspected post hoc, is shown to arise predominantly from shared reporting-lab denominators or sampling artifacts rather than any biologically plausible HGT-linked mechanism (validated against genomic surveillance ground truth, e.g., ResFinder/plasmid-typing datasets where available).
  • Performance does not replicate across ≥2 independent held-out geographic blocks (e.g., train on Europe+Americas, test on Africa+SE Asia) — i.e., overfits to region-specific reporting idiosyncrasies.
  • No genomic/molecular corroboration (plasmid or mobile genetic element detection coincident with predicted HGT windows) can be found in any subset of cases with available WGS data, undermining the mechanistic claim even if the statistical forecast partially works.

Spine & Adversarial ReadReady for validation

“This hypothesis tests whether cross-drug correlated low-amplitude oscillations in WHO GLASS country-level antibiogram time series, as detected by a multivariate LSTM, provide a statistically robust and mechanistically HGT-linked early-warning signal for MDR pathogen emergence at least 18 months before threshold-level clinical resistance is observed.”

  • highGLASS country-level data is known to be sparse, non-randomly sampled, and inconsistent in denominator/lab-enrollment methodology across years and countries; any 'signature' the LSTM learns may reflect surveillance-system artifacts (new labs joining, changed testing panels) rather than true biological HGT events.
    Partially addressed via the shuffle-channel ablation and genomic-corroboration cross-check in the protocol, but the EVP cannot fully resolve this without facility-level or isolate-level metadata linking reporting-system changes to each apparent 'emergence' event — this remains an open gap requiring GLASS metadata access not guaranteed to be available.
  • highWhy LSTM specifically, rather than simpler and more interpretable multivariate models (VAR, dynamic factor models, or even a straightforward multivariate anomaly-detection method) given the very small effective sample size (likely <40 positive events, tens of countries)? An LSTM is a high-capacity model poorly suited to this low-N regime and risks overfitting while offering no interpretability into *why* it flags a signal as HGT-like.
    The protocol requires LSTM to beat both ARIMA and GBT baselines by a pre-specified margin (10pp AUROC) precisely to justify the added model complexity; if it fails to clear this bar the correct conclusion is that simpler multivariate statistical models (e.g., VAR-based Granger causality across drugs) are the more defensible methodology — this comparison is built into the protocol but the EVP does not pre-commit to abandoning LSTM in favor of VAR if the margin isn't met, which should be made an explicit abort/pivot rule rather than left implicit.
  • mediumThe distinction between horizontal gene transfer and clonal (vertical) spread of an already-multidrug-resistant strain is a genomics question, not a statistical time-series question; a purely phenotypic resistance-frequency signal cannot, in principle, distinguish these two mechanisms without genomic/plasmid data, so the 'HGT' framing may be mechanistically unfalsifiable from GLASS data alone.
    Explicitly acknowledged as a gap: the protocol restricts strong mechanistic HGT claims to the small genomically-annotated subset (Step 10/12) and requires the primary success claim to be downgradable to a purely statistical 'early-warning signal' (agnostic to HGT-vs-clonal mechanism) if genomic concordance is inconclusive — this is the honest fallback position and should be the default reported result unless genomic corroboration clears its own threshold.

Experimental Protocol

Minimum viable test (MVT), ~6-8 weeks, single analyst + 1 ML engineer:

  1. Extract all GLASS country×pathogen×antibiotic annual resistance-frequency series 2016-2023 (public WHO GLASS data portal).
  2. Define emergence-event label: prevalence crosses from <10% to ≥20% within any 24-month window, per pathogen-drug-country triple; require ≥3 prior years of data to qualify as a "predictable" event.
  3. Hold out entire countries (not just time windows) for test set — geographic block cross-validation (leave-region-out), 5 folds by WHO region.
  4. Train (a) proposed multivariate LSTM using all drugs/pathogens per country as joint input channels, and (b) two baselines: univariate ARIMA/exponential-smoothing per drug, and gradient-boosted trees on hand-engineered lag/slope/volatility features.
  5. Score sensitivity, specificity, lead-time distribution, and AUROC/AUPRC at matched operating points across all three models.
  6. Run ablation: shuffle drug-channel identity (destroy true cross-drug correlation structure but preserve marginal statistics) — if performance is unchanged, the "HGT cross-drug signature" claim is falsified regardless of raw accuracy.
  7. Where WGS/plasmid surveillance data exists for a subset (e.g., ECDC EARS-Net linked genomic studies, or published outbreak reports), manually cross-check whether flagged "early warning" windows coincide with documented HGT events versus clonal spread.
Required datasets:
  • WHO GLASS AMR surveillance data (public, country-year-pathogen-antibiotic resistance frequencies), 2016–2024 releases.
  • ECDC EARS-Net (Europe) as an independent, higher-resolution corroboration/replication dataset.
  • CDC NARMS / ResistanceMap (CDDEP) as secondary US/global corroboration sources.
  • Subset with linked genomic/plasmid surveillance for mechanistic validation: NCBI Pathogen Detection database, PATRIC/BV-BRC AMR + genome data, published outbreak WGS studies (e.g., mcr-1, blaNDM-1, blaKPC plasmid-tracking literature).
  • Compute environment: standard Python time-series stack (PyTorch/TensorFlow, statsmodels, sktime, tslearn); no GPU-heavy foundation models required — series are low-dimensional (tens of drugs × few hundred country-years).
  • No overlap whatsoever with MS transcriptomics datasets (GSE193770, GSE108000, GSE138614, CELLxGENE, GTEx) — those are biologically and structurally irrelevant to this hypothesis and are explicitly NOT required.
Success:
  • Primary: sensitivity ≥80% for emergence detection at specificity ≥80% (≤1 false alarm per country-pathogen-drug series per 5 years), on leave-region-out test folds, pre-registered threshold.
  • Median lead time ≥18 months among true positives, with lower 95% CI bound ≥12 months.
  • LSTM outperforms both univariate ARIMA and GBT baselines by ≥10 percentage points AUROC, and outperforms shuffle-channel ablation by ≥10 points sensitivity at matched specificity (demonstrates cross-drug signal is real, not spurious).
  • ≥50% concordance between flagged early-warning windows and independently documented HGT/mobile-element events in the genomically-annotated subset (n≥10 cases minimum for this claim to be evaluable at all).
  • Results replicate directionally (even if not identically) in at least 2 of 5 geographic held-out folds and in the independent ECDC EARS-Net dataset.
Failure:
  • Sensitivity <60% at matched specificity, or performance statistically indistinguishable from univariate baseline (p>0.05 permutation test).
  • Median lead time <6 months or not significantly different from zero.
  • Shuffle-channel ablation performs equivalently to true-channel model (cross-drug correlation carries no information — falsifies core HGT-signature mechanism claim even if raw forecasting "works" for other reasons).
  • Fewer than 15 qualifying emergence events exist across all GLASS data with sufficient history — insufficient statistical power to evaluate the 80% sensitivity claim at all (a "data-insufficiency" failure distinct from a "hypothesis-wrong" failure, but operationally a stop condition).
  • No genomic corroboration achievable for any flagged window (dataset linkage failure) — mechanistic claim remains untestable and must be downgraded to a purely statistical forecasting claim.

80

GPU hours

50d

Time to result

$18,000

Min cost

$95,000

Full cost

ROI Projection

Commercial:

Moderate-to-high if validated: licensable as a SaaS early-warning module for public health agencies, global health NGOs (Gates Foundation, Wellcome Trust AMR programs), and pharma antimicrobial-stewardship/pipeline-prioritization units (informs which resistance mechanisms to target next in drug development). Low direct commercial value if only the statistical forecasting claim holds without mechanistic HGT corroboration (becomes a generic anomaly-detection product, still useful but less differentiated and easier for competitors to replicate with simpler baselines).

TIME_TO_RESULT_DAYS: 50

Implementation Sketch

# 1. Data prep
tensor[country][pathogen][antibiotic][year] = resistance_frequency  # from GLASS
labels[country][pathogen][antibiotic] = emergence_event(t0, threshold=0.20, from_below=0.10, window=24mo)

# 2. Baselines
for each (country,pathogen,antibiotic):
    fit_ARIMA(series)              -> baseline_1_score
    fit_GBT(lag_features(series))  -> baseline_2_score

# 3. LSTM model
class MDRLSTM(nn.Module):
    def __init__(self, n_drugs, hidden=32, layers=2):
        self.lstm = nn.LSTM(input_size=n_drugs, hidden_size=hidden,
                             num_layers=layers, dropout=0.2, batch_first=True)
        self.head = nn.Linear(hidden, 1)  # sigmoid -> P(emergence within 24mo)

    def forward(self, x):              # x: [batch, lookback_periods, n_drugs]
        out, _ = self.lstm(x)
        return torch.sigmoid(self.head(out[:, -1, :]))

# 4. Cross-validation
for region in WHO_REGIONS:
    train = countries not in region
    test  = countries in region
    model = train_LSTM(train, class_weight=inverse_freq(labels))
    eval_sensitivity_specificity_leadtime(model, test)

# 5. Critical ablation
shuffled_x = shuffle_drug_channels(x)   # break cross-drug correlation, keep marginals
ablation_score = eval(model_trained_on_shuffled, test)
assert true_channel_score - ablation_score >= 10pp   # else core claim falsified

# 6. Mechanistic check
for flagged_window in early_warnings:
    check_overlap(flagged_window, genomic_HGT_events_from_NCBI_PathogenDetection)
Abort checkpoints:
  • Day 10: If <15 qualifying emergence-event labels exist after data audit, abort/rescope (insufficient statistical power) rather than proceeding to modeling.
  • Day 25: If shuffle-channel ablation ties true-channel model performance, abort the mechanistic HGT-signature claim immediately — pivot to reporting as pure statistical anomaly-detection result (different, weaker claim) rather than continuing to optimize.
  • Day 35: If leave-region-out sensitivity is <60% at matched specificity, abort before investing in genomic-corroboration analysis (Phase 7 of methodology).
  • Day 45: If genomic corroboration subset yields <5 usable linked cases, flag mechanistic-validation arm as inconclusive-by-data-availability rather than claiming success or failure.

NAMED_EXPERTS: []

CLOSEST_EXISTING_WORK: []

NOVELTY_NARROWING_REQUIRED: false

Source

AegisMind Research
Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started